News&lnfo
RecBio is a high-tech enterprise jointly founded by the former vaccine R & D expert team from the Chinese Center for Disease Control and Prevention (China CDC) and the senior vaccine industrialization team.
The company has established a leading domestic R & D and innovation platform for new adjuvants, genetic engineering, and immune evaluation.

COVID-19 vaccines about to be produced in Taizhou!

  • Categories:Company Trends
  • Author:Xie Rong
  • Origin:Published by Taizhou
  • Time of issue:2020-11-26
  • Views:0

(Summary description)On the morning of November 23, the news of the official kick-off of the COVID-19 vaccine industrialization base of Jiangsu Rec-Biotechnology Co., Ltd caught the eyes of the public.

COVID-19 vaccines about to be produced in Taizhou!

(Summary description)On the morning of November 23, the news of the official kick-off of the COVID-19 vaccine industrialization base of Jiangsu Rec-Biotechnology Co., Ltd caught the eyes of the public.

  • Categories:Company Trends
  • Author:Xie Rong
  • Origin:Published by Taizhou
  • Time of issue:2020-11-26
  • Views:0
Information

On the morning of November 23, the news of the official kick-off of the COVID-19 vaccine industrialization base of Jiangsu Rec-Biotechnology Co., Ltd caught the eyes of the public.

"The experimental data have turned out to be even more encouraging than expected and we are quite confident!" Liu Yong, Chairman of RecBio, stressed. RecBio is a model high-tech company with scientists as its core entrepreneurial team members. Its main entrepreneurial members are former vaccine R&D experts from the Chinese Center for Disease Control and Prevention (China CDC) and senior vaccine industrialization professionals. More than half of its employees have master's or doctorate degrees.

 

In mid-May this year, RecBio cooperated with Jiangsu Provincial Center for Disease Control and Prevention as well as Taizhou Medical Zone, to launch the first R&D project on recombinant COVID-19 vaccine in Jiangsu province. The total investment of the project is not less than CNY 500 million, mainly in the construction of a production workshop for stock solution of COVID-19 vaccine, packaging workshop, new adjuvant workshop, quality testing center and other supporting facilities. It is expected to achieve an annual production capacity of 100 million doses in the first quarter of 2021, and 300 million doses in the second half of 2021.

 

In terms of vaccine technology route, there are traditional inactivated vaccines, recombinant protein vaccines by using innovative biotechnology, viral vector vaccines, and nucleic acid vaccines, etc. "Of all the technology routes, only recombinant protein vaccines can achieve rapid expansion of production by quickly utilizing the remaining capacity of pharmaceutical companies. Based on the long-term consideration of the pandemic, we chose to develop recombinant protein vaccines," Liu Yong said. Once there is a pandemic crisis, RecBio vaccines can be immediately commissioned to be co-produced by several biopharmaceutical companies with the approval of the nation to meet the national and even global needs.

 

What are the advantages of RecBio COVID-19 vaccine?

 

The two main factors that determine the performance of a vaccine are antigen and adjuvant. "This is exactly our strength. RecBio's recombinant COVID-19 vaccines enjoy a leading position in the industry from the initial design concept to the application of technology platforms," introduced Liu Yong.

 

In terms of the design concept, we have adopted the neutralizing antibody-guided and protein structure-based vaccine design concept invented by Professor Zhu Fengcai at the Jiangsu Provincial Center for Disease Control and Prevention, which tops the world and has applied for a patent. In terms of technology platforms, the company has two powerful R&D platforms for the immunogen optimized design and new adjuvants, respectively, which perfectly fit with Prof. Zhu Fengcai's advanced concept.

 

At present, the RecBio is about to conduct clinical trials on its COVID-19 vaccines, which are scheduled to be launched in the second half of next year. In addition to the COVID-19 vaccines, RecBio is also accelerating its development of other vaccines such as HPV vaccines and herpes zoster vaccines, with more products to be launched in Taizhou in the future.

Scan the QR code to read on your phone

  • TOP   

Contact Us

Jiangsu Rec-Biotechnology Co., Ltd.

tel:+86-523-86818860

 

Address: Vaccine Engineering Center, China Medical City, Taizhou

Copyright © 2020 Jiangsu Rec-Biotechnology Co., Ltd.  All rights reserved.      苏ICP备19043567号-1